Is this a real reason behind $MRNA not rushing Ph3, possibly reconsidering lower dosage after seeing $Pfe $bntx published data. With so much on the line, well designed trial protocol is most important part of Ph3 success. Investors eager peer reviewed data
https://t.co/7V9R4z9DJy